BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
|Articles|April 1, 2019
- Pharmaceutical Executive-04-01-2019
- Volume 39
- Issue 4
Pharmaceutical Executive, April 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Biosimilars Name Game Remains Thorny Issueover 7 years ago
HBA's Woman of the Year 2019over 7 years ago
Sharing Your Voiceover 7 years ago
Health Technology’s Double-Edged Swordover 7 years ago
True Grit: Talent Management from the Ground Upover 7 years ago
Reinventing Pharma’s Talent Searchover 7 years ago
Hiring a Chief Diversity Officerover 7 years ago
Are Pharma Marketers Fighting the Last War?over 7 years ago
Ready Patient Oneover 7 years ago
Country Report: ChinaAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5